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Abstract
Introduction: Whether red blood cell (RBC) transfusion is beneficial remains controversial. In both retrospective and
prospective evaluations, transfusion has been associated with adverse, neutral, or protective effects. These varying
results likely stem from a complex interplay between transfusion, patient characteristics, and clinical context. The
objective was to test whether age, comorbidities, and clinical context modulate the effect of transfusion on survival.
Methods: By using the multiparameter intelligent monitoring in intensive care II database (v. 2.6), a retrospective
analysis of 9,809 critically ill patients, we evaluated the effect of RBC transfusion on 30-day and 1-year mortality.
Propensity score modeling and logistic regression adjusted for known confounding and assessed the independent
effect of transfusion on 30-day and 1-year mortality. Sensitivity analysis was performed by using 3,164 transfused
and non-transfused pairs, matched according the previously validated propensity model for RBC transfusion.
Results: RBC transfusion did not affect 30-day or 1-year mortality in the overall cohort. Patients younger than
55 years had increased odds of mortality (OR, 1.71; P< 0.01) with transfusion. Patients older than 75 years had lower
odds of 30-day and 1-year mortality (OR, 0.70; P < 0.01) with transfusion. Transfusion was associated with worse
outcome among patients undergoing cardiac surgery (OR, 2.1; P< 0.01). The propensity-matched population
corroborated findings identified by regression adjustment.
Conclusion: A complex relation exists between RBC transfusion and clinical outcome. Our results show that
transfusion is associated with improved outcomes in some cohorts and worse outcome in others, depending
on comorbidities and patient characteristics. As such, future investigations and clinical decisions evaluating the
value of transfusion should account for variations in baseline characteristics and clinical context.
Introduction
In critically ill patients, anemia is common; about 95%
of intensive care unit (ICU) patients have abnormally
low hemoglobin levels by ICU day 3 [1]. The transfusion
trigger of “30/10” (HCT, <30%; hemoglobin, <10 g/dl)
was suggested in a case series of trauma patients as early
as 1942. Several clinical trials conducted over the past two
decades have shown at least equivalent outcomes when a
more-conservative transfusion threshold of hemoglobin
7 g/dl is applied to a critically ill patient population [2-5],
whereas other prospective and retrospective studies have
shown a hazard associated with RBC transfusion >7 g/dl
in a variety of patient populations [3,4,6-12]. This hetero-
geneity in outcomes suggests that the impact of RBC
transfusion on mortality varies depending on the patient
population studied, the transfusion threshold used, and
the age of the RBCs transfused [13]. Multivariate regres-
sion analysis, adjusting for illness severity, reported that
RBC transfusion was not associated with an increase in
mortality among ICU patients. In fact, a protective effect
at 30 days was noted after propensity score matching
[9,14,15]. For patients with cardiovascular disease, the
relation between RBC transfusion and clinical outcome is
even more complex. Data from almost 79,000 patients
[16] older than 65 years who had been hospitalized with a
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association between the RBC transfusion and improved
outcomes in elderly patients when admission hematocrit
values were <33%. Conversely, other retrospective trials
have consistently shown that RBC transfusions are
associated with adverse outcome in patients undergo-
ing coronary bypass surgery or acute coronary syn-
drome [17]. The recent randomized, single-center TRACS
(Transfusion Requirements after Cardiac Surgery) trial
compared a restrictive with a liberal strategy (transfusion
for hematocrit <24% or <30%, respectively), and reported
no difference in the composite end point of 30-day mor-
tality and morbidity (cardiogenic shock, acute respiratory
distress syndrome, or acute kidney injury) [18].
We hypothesize that these varying results stem from a
complex interplay between RBC transfusion, patient
characteristics, and clinical context. Specifically, we aim
to test whether age, comorbid conditions, and clinical
context modulate the effect of RBC transfusion on mor-
tality. We therefore analyzed the impact of RBC transfu-
sion in the critical ill not only in the overall population
but also in clinically important subgroups of patients in
the Multiparameter Intelligent Monitoring in Intensive
Care II (MIMIC-II) database.
Methods
The MIMIC-II database (v2.6) is a publicly available clin-
ical database developed by the Massachusetts Institute of
Technology (MIT), Phillips Healthcare, and Beth Israel
Deaconess Medical Center (BIDMC) [19]. MIMIC-II is a
repository of de-identified administrative, clinical, and
survival outcome data from more than 32,000 critically ill
patients treated in the ICUs at BIDMC from 2001 through
2008. These data include clinical variables such as patient
age, gender, and chronic disease diagnoses, as represented
by International Classification of Diseases (ICD) codes; la-
boratory data such as hematocrit, serum chemistry, and
microbiology; physiological data such as blood pressure
and heart rate; markers of treatment intensity such as the
utilization of mechanical ventilation, renal-replacement
therapy, central venous catheters, vasopressors, and blood
transfusion; and survival to and after hospital discharge.
All data have been de-identified before being archived in
the MIMICII database. Patient data were collected only
during the patient’s ICU stay. Survival data were obtained
from the Social Security database and were available
through 2012. All patients admitted (or health care prox-
ies in case the patient could not give informed consent on
admission) to any of the intensive care units at the Beth
Israel Deaconess gave written informed consent to allow
data collection during their ICU stay. These data are
stored in the MIMICII database.
The Institutional Review Board of the Beth Israel
Deaconess Medical Center (BIDMC) and Massachusetts
Institute of Technology have approved the use of the
MIMMICII database by any investigator who fulfills data-
user requirements. The database is freely accessible to the
research community at large. All research was performed
in compliance with the Helsinki Declaration describing
ethical principles for medical research involving human
subjects. During the study period, only leukodepleted
blood was transfused at the hospital where the data were
collected. The mean age of RBCs transfused at the hos-
pital is 28 days.
The primary study population consisted of adult
patients who were admitted to the medical ICU (MICU),
surgical ICU (SICU), coronary care unit (CCU), or cardiac
surgery recovery unit (CSRU). Inclusion criteria were the
occurrence of a nadir hematocrit between 20% and 30%
and age of 18 years or older. The nadir hematocrit was
used for non-transfused patients, and the pre-transfusion
value, for transfused patients. Trauma patients (identified
by ICD-9 code and location in the trauma ICU) were
excluded. We excluded trauma patients because some of
these patients receive transfusion in the prehospital set-
ting. This information is not currently consistently cap-
tured in the database. Patients who had multiple hospital
ICU admissions during the study period were excluded to
avoid associating management strategies used during mul-
tiple admissions over the study period to a single mortality
outcome. For example, if a patient died within a year of
two separate ICU admissions, and the transfusion strategy
differed during these two admissions, it would be difficult
to determine whether death were associated with the first
or the second admission.
The primary end point for the study was 30-day mor-
tality, and the secondary end point was 1-year mortality.
The relation between RBC transfusion, 30-day mortality,
and 1-year mortality was examined by using a logistic re-
gression model with the exposure of interest (RBC trans-
fusion or no transfusion) adjusted for the propensity to
receive RBC transfusion. A previously validated propensity
score model [14] was used to adjust for the likelihood of a
patient receiving a RBC transfusion. The variables used
for the propensity model are shown in Table 1. The results
of this analysis are subsequently referred to as propensity
score-adjusted analysis.
A subcohort with patients matched according to
their propensity score was created. A “greedy” matching
algorithm that matched patients in a 1:1 ratio based on
propensity score with a caliper width of 0.2, without
replacement, was used. Within the propensity matched
subcohort, subsequent logistic regression was performed
to evaluate the effect of RBC transfusion on the primary
and secondary end points adjusted for the propensity to
receive RBC transfusion.
Results from this analysis are referred to as the matched
analysis. A P value of <0.05 was significant. The effect of
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in the prespecified groups is listed in Table 2 for both the
initial unmatched and the matched cohorts of patients.
All statistical analyses were performed by using MATLAB
version R2010b (MathWorks, Natick, MA, USA) with
additional processing of data in Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA, USA) and in R
2.15.1. Matching was performed by using the MatchIt
package. For each model, patients with missing data were
excluded.
Results
There were 32,425 patients in the MIMIC database, and
12,634 patients met inclusion criteria. Patients were
Table 1 Description of propensity score model
Coefficient Odds ratio (95% Confidence i Interval] P>z
Age, per year 0.01 1.01 1.01 1.02 0.00
Gender (female) -0.09 0.91 0.83 1.00 0.06
Solid cancer -0.08 0.92 0.82 1.04 0.19
Hematologic cancer -0.15 0.86 0.65 1.15 0.32
Cirrhosis 0.47 1.60 1.24 2.07 0.00
Congestive heart failure -0.18 0.84 0.74 0.94 0.00
Diabetes 0.28 1.32 1.19 1.47 0.00
SAPS I, per point -0.02 0.98 0.89 1.08 0.67
Sepsis 0.07 1.08 1.06 1.09 0.00
Respiratory disease 0.09 1.10 0.96 1.26 0.19
SOFA expiratory, per point 0.06 1.06 1.02 1.11 0.00
SOFA epatic, per point 0.17 1.18 1.09 1.28 0.00
SOFA ematologic, per point 0.20 1.22 1.15 1.30 0.00
SOFA Renal, per point -0.10 0.91 0.86 0.96 0.00
SOFA CNS, per point -0.18 0.84 0.80 0.87 0.00
SOFA Cardiovascular, per point 0.24 1.28 1.21 1.34 0.00
Mechanical ventilation 0.56 1.74 1.54 1.97 0.00
Hemofiltration/Hemodialysis 0.53 1.71 1.32 2.21 0.00
Hematocrit, per percentage -0.27 0.77 0.75 0.78 0.00
Constant 4.07 58.32 34.63 98.24 0.00
Table 2 Propensity-score analysis results for entire cohort
30-day mortality 1-year mortality
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
All 0.955 (0.844-1.082) 0.469 1.013 (0.916-1.120) 0.803
Medical 1.022 (0.848-1.232) 0.817 1.035 (0.874-1.225) 0.693
Surgical, noncardiac 0.801 (0.620-1.035) 0.09 0.861 (0.701-1.058) 0.155
Surgical, cardiac 2.11 (1.316-3.385) 0.002 1.807 (1.351-2.418) <0.001
Acute cardiac 0.754 (0.542-1.048) 0.093 0.791 (0.607-1.031) 0.083
Nonacute cardiac 1.157 (0.793-1.688) 0.449 1.35 (1.031-1.768) 0.029
Cancer 0.985 (0.777-1.249) 0.9 0.949 (0.775-1.162) 0.614
GI bleed 0.889 (0.542-1.459) 0.642 1.296 (0.840-1.998) 0.241
SAPS <16 1.24 (1.015-1.514) 0.035 1.143 (0.986-1.326) 0.077
SAPS
3 16 0.818 (0.698-0.958) 0.013 0.929 (0.811-1.065) 0.291
Age <55 years 1.711 (1.222-2.396) 0.002 1.362 (1.041-1.783) 0.024
Age 55 to 75 years 1.167 (0.953-1.429) 0.136 1.208 (1.030-1.416) 0.02
Age >75 years 0.704 (0.588-0.843) <0.001 0.802 (0.689-0.934) 0.005
Bold numbers highlight significant differences.
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patients for analysis. Among these, 4,587 patients were
given transfusions, and 5,222 patients were not (Figure 1).
To assess bias from excluding patients due to missing
data, baseline characteristics of excluded patients are
shown in Additional file 1 of the supplemental data sec-
tion (2,513 of the 2,825 total excluded patients; 312 pa-
tient did not have patient characteristics available to us).
Significant baseline differences were found of the patients
included versus those that were excluded for this analysis.
The excluded patients had similar 30-day mortality and
higher 1-year mortality than the study patient population.
SAPS (Simplified Acute Physiology Score) and SOFA
(Sequential Organ Failure Assessment) scores were calcu-
lated on day of admission. The median SAPS was used to
make the variable binary.
The clinical characteristics of the entire cohort are
summarized in Table 3. Transfused patients were older,
had a lower hematocrit, were sicker, as determined by
SAPS and SOFA scores, and had more comorbidities, as
defined by the Elixhauser score.
The majority of patients received two RBC transfusions
during the hospital stay, and most of the RBC transfusion
occurred in the first week, 3 days of hospitalization (see
Additional file 2 in the supplemental data section). In the
overall population, as well as in the matched cohort, no
significant association was noted between RBC transfusion
and 30-day and 1-year mortality by using propensity-score
analysis (see Tables 2 and 4). Timing of transfusion (as a
continuous variable) during the ICU stay did not have an
impact on 30-day and 1-year mortality (data not shown).
RBC transfusion was, however, associated with varying
effects on mortality in the subgroups. We first describe
the results for the entire cohort and then present the re-
sults by using the matched subcohort. In the propensity-
score analysis of the entire cohort, transfused patients
who were less acutely ill (SAPS <16) as measured by
SAPS, had higher 30-day mortality (OR, 1.24; P < 0.04;
CI, (1.02 to 1.51). Patients with higher SAPS scores
(SAPS ≥16) had lower 30-day mortality with RBC trans-
fusion (OR, 0.82; P= 0.01; CI, 0.70 to 0.96). Patients
undergoing cardiac surgery who were transfused demon-
strated the greatest odds of death at 30 days after adjust-
ment for the propensity score (OR, 2.1; P< 0.01; CI, 1.32
to 3.39). The increased mortality persisted at 1 year
(OR, 1.81; P<0.001; CI, 1.35 to 2.42). Younger patients
(age <55 years) had significantly worse outcomes with
RBC transfusion at both 30 days (OR, 1.71; P<0.01; CI,
1.22 to 2.40) and at 1 year (OR, 1.36; P=0.03; CI, 1.04 to
1.78). Among patients in the highest tertile of age
(age >75 years), RBC transfusion was associated with re-
duced mortality at 30 days (OR, 0.70; P<0.001; CI, 0.59 to
0.84) and at 1 year (OR, 0.80; P<0.01; 0.69 to 0.93).
After propensity-score matching, 2,167 nontransfused
and 1,532 transfused patients were excluded, leaving a
matched cohort of 3,055 patients in each group (Figure 1).
Propensity-score matching improved the balance of
baseline characteristics significantly (see Additional file 3
in supplemental section). Propensity-score matching, how-
ever, was not able to achieve a perfect balance between
transfused and nontransfused patients. The propensity-
score model is well calibrated, as depicted in Additional
file 4 in the supplemental data section. After match-
ing, the standardized mean differences, d, for most
baseline characteristics between the two treatment groups
were less than 10%, indicating a small magnitude of
difference.
Nadir hemoglobin was significantly associated with
30-day mortality even after the propensity-score
matching, and was added to the regression model in
addition to the propensity score. Consistent with the
findings in the propensity-score analysis in the initial
cohort, propensity-matched patients in the lowest
tertile of age had greater odds of 30-day mortality
with transfusion (OR, 1.65; P =0.01; CI, 1.10 to 2.47).
For patients in the highest tertile of age, transfusion
was associated with decreased mortality at 30 days
(OR, 0.66; P <0.0001; CI: 0.54-0.80) of age. Again,
cardiac surgery patients who were transfused showed
much worse outcomes at both 30 days (OR, 1.83; P=0. 03 ;
CI, 1.06 to 3.17) and 1-year (OR, 1.47; P =0 . 0 3; CI ,
1.04 to 2.08).
32,425 Patients in MIMIC
12,634 Patients
19,791 Patients 
not meeting
inclusion criteria 
9,809 Patients
2,825 Patients 
with missing data
Regression adjusted
Analysis
Matched Propensity 
Score Analysis
4,587 5,222 3,055 3,055
RBC Transfused
No RBC Transfusion
Figure 1 Description of study design.
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senting with gastrointestinal bleed (GIB) revealed that
three fourths of GIB patients were transfused among
patients whose hemoglobin reached a nadir between 7 and
10 g/dl. After adjusting for propensity to transfuse, no sig-
nificant benefit or harm was found from RBC transfusion
in these patients at 30 days (OR, 0.64; P= 0.17; CI, 0.34 to
1.2) or at 1 year (OR, 1.02; P=0.95; CI, 0.61 to 1.69).
Bootstrapping of the matched cohort propensity-score
analysis by using 1,000 iterations that leave out 50
patients during each iteration validated the findings as
listed in Table 4 (data not shown).
Table 3 Description of entire study cohort
Patients by transfusion status
All patients Transfused Nontransfused
(n= 9,809) (n= 4,587) (n= 5,222) Pd
Age, years* 68 (55.7~ 78.6) 70.4 (58.3~ 79.5) 65.7 (53.5~77.5) <0.001 0.239
Female (%) 44.12% 43.73% 44.47% 0.465 0.015
Male (%) 55.88% 56.27% 55.53% 0.465 0.015
Transfused patients (%) 46.76% 100.00% 0.00% ——
Nadir hematocrit, percentage* 25.7 (23.6~ 27.6) 24.8 (22.9~ 26.6) 26.6 (24.5~28.3) <0.001 0.657
Nadir hemoglobin, percentage* 8.6 (7.8~9.3) 8.2 (7.5~9) 8.9 (8.1~9.5) <0.001
SAPS I score, point 15 (12~19) 17 (13~20) 14 (11~18) <0.001 0.464
SOFA score, point 7 (4~9) 8 (5~11) 6 (3~8) <0.001 0.43
Elixhauser Comorbidity, point 2 (1~4) 2 (1~4) 2(1~4) <0.001 0.086
Medical patients (%) 29.66% 28.28% 30.87% 0.005 0.057
Acute cardiac patients (%) 12.67% 14.45% 11.11% <0.001 0.1
Surgical patients, noncardiac (%) 24.21% 22.59% 25.64% <0.001 0.071
Surgical patients, cardiac (%) 33.46% 34.68% 32.38% 0.016 0.049
Nonacute cardiac patients 26.72% 28.45% 25.20% <0.001 0.073
Hematologic cancer patients (%) 2.58% 2.90% 2.30% 0.061 0.038
Solid cancer patients (%) 16.06% 16.07% 16.05% 0.979 <0.001
Sepsis patients (%) 15.99% 19.03% 13.31% <0.001 0.156
GI bleed patients (%) 6.41% 10.18% 3.10% <0.001 0.287
*ks test P< 0.0001.
*#median (IRQ) is reported.
Table 4 Results of propensity score-matched cohort
30-day mortality 1-year mortality
Studies Cohort size Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Transfused versus nontransfused 6110 0.93 0.81~ 1.07 0.34 0.96 0.85~ 1.07 0.45
Medical ICU (MICU) 1792 1.09 0.89~ 1.35 0.40 1.16 0.96~ 1.4 0.13
Surgical, noncardiac 1360 0.76 0.57~ 1.03 0.08 0.80 0.63~ 1.02 0.07
Surgical, cardiac 2076 1.83 1.06~ 3.17 0.03 1.47 1.04~ 2.08 0.030
Acute cardiac 849 0.77 0.53~ 1.12 0.20 0.79 0.59~ 1.06 0.12
Nonacute cardiac 1676 1.29 0.82~ 2.05 0.27 1.30 0.92~ 1.92 0.13
Cancer 1215 1.06 0.81~ 1.38 0.69 0.88 0.70~ 1.11 0.29
GI bleed 332 0.64 0.34~ 1.20 0.17 1.02 0.61~ 1.69 0.95
SAPS <15 2441 1.40 1.08~ 1.8 0.01 1.20 1~1.46 0.05
SAPS ≥15 3657 0.80 0.67~ 0.94 0.01 0.85 0.74~ 0.97 0.03
Age <55 years 1308 1.65 1.1~2.47 0.01 1.27 0.92~ 1.75 0.15
Age 55 to 75 years 2616 1.21 0.95~ 1.54 0.12 1.24 1.03~ 1.5 0.02
Age >75 years 2152 0.66 0.54~ 0.82 0.0001 0.73 0.61~ 0.87 0.0001
Bold numbers highlight significant differences.
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Considerable uncertainty remains regarding who might
benefit from RBC transfusion and what is the appro-
priate threshold for transfusion. Our present analysis
suggests a complex relation between patient characteris-
tics, clinical context, and outcome. By using regres-
sion with adjustment for propensity to transfuse, we
observed no significant benefit or harm with RBC transfu-
sions in the entire cohort. However, we observed signi-
ficant RBC transfusion treatment-effect heterogeneity.
In particular, a relation was found between age and
outcomes after transfusion. Younger patients derived
harm, whereas older patients benefited from transfusion.
Moreover, cardiac surgery patients who were transfused
consistently had markedly worse short- and long-term
mortality.
After the pivotal randomized controlled trial of
Hebert et al. [5], several prospective and retrospective
trials have shown that RBC transfusions are associ-
ated with increased mortality in critically ill patients
[4], patients with burns [20], cardiac surgery patients
[12], and in patients with acute coronary syndromes
[6]. Recent trials, however, have challenged the emer-
g i n gd o g m at h a tR B Ct r a n s f u s i o n sa r eu n i f o r m l y
harmful. Vincent et al. [14] performed a retrospective
analysis of the SOAP database and found that pa-
tients receiving an RBC transfusion had improved
survival. The study had a similar analysis and design
as the ABC study [4], which showed a clear harm to
patients who received RBC transfusions. Vincent and
colleagues postulated that the main difference be-
tween the ABC and SOAP trials was the proportion
of leukocyte-reduced blood used. A later study by Hebert
et al. [21] also showed that leukocyte-reduced blood
improves outcome. We propose that, in addition to
leukocyte reduction, patient characteristics and clinical
context may play an important role in predicting outcome
of RBC transfusion.
The randomized clinical trial of Hebert suggested
improved outcome with a conservative approach to
transfusion. In the study, the benefit of a conservative
strategy was greater among younger patients and those
with an APACHE II score <20. The results of our
analyses corroborate these findings by showing higher
mortality for both younger and less-ill patients who were
transfused. We extend Hebert’s observations by show-
ing older and sicker patients who received RBC trans-
fusions had a lower adjusted mortality. This finding
has important clinical implications. These data suggest
that universal transfusion protocols may be harmful and
that the decision to transfuse should include assess-
ment of factors including patient demographics and
clinical context. RBC transfusion should not be viewed
as uniformly hazardous, and the recent adoption of
conservative transfusion practice across the board should
be reevaluated.
Moreover, our findings may help reconcile reports
describing discrepant clinical outcomes after RBC trans-
fusion on clinical outcome in the literature. For example,
the analysis of 79,000 Medicare patients with acute cor-
onary syndrome and a mean age 78 years showed that
RBC transfusion was associated with increased survival.
The study was contested because it was not consistent
with the findings of Hebert et al. The discrepancy may
be in part attributable to the ages of the Medicare
patients [16].
A consensus has emerged to limit RBC transfusion in
the absence of evidence of end-organ ischemia. Previ-
ously, two exceptions to this rule were GI bleeding and
patients with coronary artery disease. A recent random-
ized controlled study by Villanueva et al. [22] showed a
survival benefit for patients presenting with active GI
bleed when treated with a conservative transfusion strat-
egy. In our analyses of patients with GI bleeding, RBC
transfusion did not have an impact on mortality. However,
our analysis has to be interpreted with caution because of
low numbers of patients who were not transfused, limiting
the ability to identify harm or benefit from transfusion. A
population with GI bleeding 3 times larger than evaluated
in this study would be necessary to identify the effect size
(hazard ratio of 0.7), as seen in the prospective trial. How-
ever, we can exclude a larger degree of harm or benefit
associated with RBC transfusion in patients presenting
with GI bleed.
Cardiac surgery patients that were transfused had
twice the 30-day and 1-year mortality in both the entire
cohort and the matched subcohort. This corroborates
prior studies on this patient subset [12,23]. It is un-
known why these patients demonstrate higher mortality
when transfused. This could be because of confounding
that could not be identified in this cohort, such as
type of cardiac surgery, redo surgery versus not, emer-
gency versus nonemergency surgery, and so on. Surgery,
general anesthesia, and chronic coronary artery dis-
ease by itself may not explain worse outcome in pa-
tients undergoing cardiac surgery because among
noncardiac surgical patients and patients with chronic
coronary artery disease, we did not observe worse out-
comes with transfusion.
Apart from patients presenting with STEMI [24] and
elderly patients [16], RBC transfusion has in the past
been associated with harm fairly consistently among those
presenting with acute coronary syndrome [17]. The harm
from RBC transfusion has been ascribed in previous arti-
cles to the aging of blood and loss of function of RBCs
during storage [25]. In particular, a worsening of microcir-
culatory function and nitric oxide bioavailability during
storage has been described [26-28]. The finding that RBC
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with lower SAPS scores in our study may point toward a
balance of beneficial biologic effects, such as optimization
of tissue oxygen consumption and harmful effects induced
by RBC storage.
Our hypothesis is that in patients who are in a state in
which tissue oxygen consumption is independent of
oxygen delivery, harmful effects (hemolysis and NO sca-
venging) outweigh beneficial effects (increase in oxygen
delivery) of RBC transfusion. Among patients in which
oxygen consumption is dependent on adequate oxygen
delivery, however, the beneficial effects of RBC transfusion
prevail.
Many authors have stressed the need for another ran-
domized controlled trial evaluating the salutary effects of
RBC transfusion in patients with a hematocrit between
21% and 30% in the era of leukocyte-depleted blood
transfusions. We propose that such randomized con-
trolled trials should be designed to evaluate the effect in
several predefined patient subgroups. Until such data are
available, results from the present study and other obser-
vational studies suggest that it is time to move away from
the one-model-fits-all paradigm. Analysis of large data-
bases is valuable by providing hypotheses to test and, as in
our case, propose prespecified subgroup analyses to test
in other orthogonally related databases or randomized
controlled trials.
As is the case with all retrospective analyses, limita-
tions of this study include exclusion of patients with
missing data as well as an inability to identify and correct
for unmeasured confounding, as well as to prove causality
in the association of RBC transfusion and mortality; the
findings should be viewed as hypothesis generating. We
attempted to quantify and adjust for known confounding
by using modeling techniques and by analyzing baseline
characteristics of patients excluded, and we found that
excluded and selected patients have similar patient charac-
teristics. We cannot account for selection bias and cluster-
ing of outcome because of the single-center nature of the
study. Data regarding the indications for blood transfusion
and length of storage of RBCs were not available, therefore
prohibiting any inference about RBC storage and clinical
outcomes.
The practicing physician is still left with using clinical
judgment in deciding whether to transfuse critically ill
patients. The observed differences in clinical outcome
depending on patient characteristics and clinical out-
come, as demonstrated in this article, suggests the need
for further randomized investigation with predefined
subset analyses testing the influence of age and acuity
of illness. We need to develop a risk-scoring system
for RBC transfusion that estimates patient- and
context-specific benefit and risk of harm with RBC
transfusion.
Conclusions
In conclusion, we showed that RBC transfusions in a
general intensive care unit population does not increase
30-day and 1-year mortality. However, RBC transfusions
have a heterogeneous effect on clinical outcomes in sub-
groups of this critically ill cohort. Some populations,
such as cardiac surgery patients, younger patients, and
less-ill patients derive harm, whereas older and more ill
patients benefit from RBC transfusion. Additional find-
ings show trends toward worse long-term outcomes
among patients with chronic coronary artery disease
a n di m p r o v e do u t c o m e sa m o n gt h o s ep r e s e n t i n gw i t h
acute cardiac disease. Because of the retrospective na-
ture of these investigations, these findings are hypothesis
generating rather than showing a clear cause-and-effect
relation.
We hope this study encourages the research community
to take advantage of large clinical databases in this era of
digital health records and use a similar approach of iden-
tifying treatment-effect heterogeneity in the evaluation of
clinical interventions.
Key messages
 RBC transfusion does not affect 30-day mortality
in a large general critical care population,
including surgical as well as medical critically
ill patients
 The effect of RBC transfusions differs, however,
considerably, depending on patient characteristics
and clinical scenario
 Cardiac surgery patient have worse outcomes
when transfused
 Older patients as well as patients with a SAPS
score of >16 derive benefit, whereas younger
(<55 years of age) and less-ill patients
(SAPS score <16) derive harm
Additional files
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transfusion status and 30-day mortality. Squares represent percentage
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